UBS Group
CRDF icon

UBS Group’s Cardiff Oncology CRDF Stock Holding History

UBS Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$130K – 10284
2024
Q4 		$130K Buy
+30,000
New +$93.8K ﹤0.01% 6711

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

UBS Group's CRDF Position: Q1 2026 in Review

UBS Group increased its Cardiff Oncology (CRDF) stake by 358% in Q1 2026, buying an estimated $643K and bringing the position to 400,576 shares worth $649K. The position accounts for ﹤0.01% of the portfolio, ranked #5884.

UBS Group first reported a position in CRDF in Q4 2014 and has held it in 44 quarters since. The position peaked at $1.23M in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • UBS Group held 400,576 shares of Cardiff Oncology worth $649K as of Q1 2026.
  • UBS Group bought 313,147 Cardiff Oncology shares in Q1 2026, an estimated $643K.
  • Cardiff Oncology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5884 holding.
  • UBS Group first reported a position in Cardiff Oncology in Q4 2014 and has held it in 44 quarters since.
  • UBS Group's Cardiff Oncology position peaked at $1.23M in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.